Medesis Pharma SA (ALMDP.PA) Stock Price & Overview
EPA:ALMDP • FR0010844464
Current stock price
The current stock price of ALMDP.PA is 0.35 EUR. Today ALMDP.PA is down by -8.14%. In the past month the price decreased by -10.71%. In the past year, price decreased by -76.67%.
ALMDP.PA Key Statistics
- Market Cap
- 1.771M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
ALMDP.PA Stock Performance
ALMDP.PA Stock Chart
ALMDP.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALMDP.PA. When comparing the yearly performance of all stocks, ALMDP.PA is a bad performer in the overall market: 97.88% of all stocks are doing better.
ALMDP.PA Earnings
ALMDP.PA Forecast & Estimates
7 analysts have analysed ALMDP.PA and the average price target is 0.82 EUR. This implies a price increase of 133.14% is expected in the next year compared to the current price of 0.35.
ALMDP.PA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALMDP.PA Ownership
About ALMDP.PA
Company Profile
Medesis Pharma SA operates as a clinical development stage biopharmaceutical company, which engages in the research and development of orally administered molecule drugs. The company is headquartered in Baillargues, Occitanie. The company went IPO on 2021-02-12. The firm is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.
Company Info
IPO: 2021-02-12
Medesis Pharma SA
L'Oree des Mas Avenue du Golf, Montpellier
Baillargues OCCITANIE FR
Employees: 10
Phone: 33467030396
Medesis Pharma SA / ALMDP.PA FAQ
Can you describe the business of Medesis Pharma SA?
Medesis Pharma SA operates as a clinical development stage biopharmaceutical company, which engages in the research and development of orally administered molecule drugs. The company is headquartered in Baillargues, Occitanie. The company went IPO on 2021-02-12. The firm is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.
What is the current price of ALMDP stock?
The current stock price of ALMDP.PA is 0.35 EUR. The price decreased by -8.14% in the last trading session.
What is the dividend status of Medesis Pharma SA?
ALMDP.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALMDP stock?
ALMDP.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the ownership structure of Medesis Pharma SA (ALMDP.PA)?
You can find the ownership structure of Medesis Pharma SA (ALMDP.PA) on the Ownership tab.